Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Net Cash Flow (2016 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Net Cash Flow for 15 consecutive years, with $372.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Cash Flow rose 421.93% year-over-year to $372.8 million, compared with a TTM value of $480.0 million through Dec 2025, up 2751.93%, and an annual FY2025 reading of $480.0 million, up 2751.93% over the prior year.
  • Net Cash Flow was $372.8 million for Q4 2025 at Neurocrine Biosciences, up from $76.4 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $372.8 million in Q4 2025 and bottomed at -$256.6 million in Q2 2024.
  • Average Net Cash Flow over 4 years is $47.3 million, with a median of $69.7 million recorded in 2025.
  • The sharpest move saw Net Cash Flow tumbled 553.36% in 2024, then skyrocketed 421.93% in 2025.
  • Year by year, Net Cash Flow stood at $165.5 million in 2021, then plummeted by 125.92% to -$42.9 million in 2023, then crashed by 169.93% to -$115.8 million in 2024, then surged by 421.93% to $372.8 million in 2025.
  • Business Quant data shows Net Cash Flow for NBIX at $372.8 million in Q4 2025, $76.4 million in Q3 2025, and $69.7 million in Q2 2025.